1 Department of Palliative Medicine, National Cancer Center Hospital East , Kashiwa, Japan .
2 Department of Palliative Medicine, Tohoku University School of Medicine , Sendai, Japan .
J Palliat Med. 2018 Nov;21(11):1636-1640. doi: 10.1089/jpm.2017.0675. Epub 2018 Jul 5.
Breakthrough cancer pain (BTcP) is a predictor of interference with general activities and poor pain management. The extent of this influence has not yet been determined.
This study aimed to investigate the influence of BTcP on general activities, and pain management in patients with controlled background pain.
Single-center prospective observational study.
SETTING/SUBJECTS: The study cohort comprised 258 consecutive patients (female, 40.0%; mean age, 64.5 years) who had received opioid medication for cancer pain for over 2 weeks.
A recommended diagnostic algorithm was used to quantitate and compare interference with general activities, average background pain intensity over the previous 24 hours (24h-PI), and achievement of personalized pain goals (PPGs) (24h-PI≤PPG) of 119 patients with and 139 patients without BTcP.
Interference with general activities, 24h-PI, and PPG scores [mean (standard deviation)] in patients with BTcP were 2.8 (2.2), 3.0 (1.7), and 1.8 (1.4), respectively, which are all significantly higher than for those without BTcP [1.3 (2.0), p < 0.01; 1.7 (1.6), p < 0.01; 1.5 (1.3), p = 0.03], respectively. A significantly smaller percentage of patients with BTcP than without BTcP achieved their PPGs (36.1% vs. 67.6%, p < 0.01).
BTcP has a negative impact on general activities and pain management. Healthcare providers should recognize that management of BTcP is important in improving general activities and management of cancer pain.
突破性癌痛(BTcP)是干扰日常活动和疼痛管理不佳的预测指标。但其影响程度尚未确定。
本研究旨在调查 BTcP 对背景疼痛得到控制的患者日常活动和疼痛管理的影响。
单中心前瞻性观察研究。
设置/研究对象:研究队列包括 258 例连续接受阿片类药物治疗癌症疼痛超过 2 周的患者(女性占 40.0%;平均年龄 64.5 岁)。
采用推荐的诊断算法来量化和比较 119 例有 BTcP 和 139 例无 BTcP 患者的日常活动干扰、过去 24 小时平均背景疼痛强度(24h-PI)和个性化疼痛目标(PPG)的达成情况(24h-PI≤PPG)。
BTcP 患者的日常活动干扰、24h-PI 和 PPG 评分[平均值(标准差)]分别为 2.8(2.2)、3.0(1.7)和 1.8(1.4),均显著高于无 BTcP 患者[1.3(2.0),p<0.01;1.7(1.6),p<0.01;1.5(1.3),p=0.03]。有 BTcP 的患者达到 PPG 的比例显著低于无 BTcP 的患者(36.1% vs. 67.6%,p<0.01)。
BTcP 对日常活动和疼痛管理有负面影响。医疗保健提供者应认识到,管理 BTcP 对于改善日常活动和癌症疼痛管理非常重要。